

Cody J Peer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2105351/publications.pdf>

Version: 2024-02-01

100
papers

3,403
citations

201674

27
h-index

155660

55
g-index

100
all docs

100
docs citations

100
times ranked

6020
citing authors

#	ARTICLE	IF	CITATIONS
1	Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 74-82.	1.6	571
2	Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. <i>Blood</i> , 2011, 117, 5827-5834.	1.4	428
3	Selumetinib in Children with Inoperable Plexiform Neurofibromas. <i>New England Journal of Medicine</i> , 2020, 382, 1430-1442.	27.0	360
4	Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 997-1008.	2.4	215
5	Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. <i>Cancer Cell</i> , 2021, 39, 566-579.e7.	16.8	107
6	Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia. <i>Clinical Cancer Research</i> , 2012, 18, 2099-2107.	7.0	103
7	A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study. <i>Clinical Cancer Research</i> , 2014, 20, 5392-5402.	7.0	83
8	IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion. <i>Clinical Cancer Research</i> , 2019, 25, 4945-4954.	7.0	82
9	Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 4633-4641.	7.0	68
10	An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5918-5926.	7.0	64
11	Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. <i>Clinical Immunology</i> , 2014, 155, 176-187.	3.2	60
12	Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology. <i>Journal of Controlled Release</i> , 2017, 268, 147-158.	9.9	57
13	A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2015, 116, 546-555.	2.5	55
14	The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. <i>Fluids and Barriers of the CNS</i> , 2018, 15, 2.	5.0	55
15	A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 645-652.	2.3	54
16	A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 880, 132-139.	2.3	45
17	Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 643-655.	3.3	43
18	Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. <i>Anti-Cancer Drugs</i> , 2018, 29, 457-465.	1.4	39

#	ARTICLE	IF	CITATIONS
19	Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics. <i>Science Translational Medicine</i> , 2021, 13, eabd8077.	12.4	38
20	Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 828-836.	7.0	35
21	<scp>First-in-Human</scp> Phase I Study of Envafolimab, a Novel Subcutaneous <scp>Single-Domain Anti-PD-L1</scp> Antibody, in Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2021, 26, e1514-e1525.	3.7	34
22	Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirusâ€“associated multicentric Castleman disease. <i>Blood</i> , 2020, 135, 2316-2319.	1.4	33
23	Effects of <i>UGT1A1</i> genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48â€“hour continuous infusion in patients with cancer. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 461-473.	2.0	32
24	Phase 1 study of the immunotoxin LMBâ€“100 in patients with mesothelioma and other solid tumors expressing mesothelin. <i>Cancer</i> , 2020, 126, 4936-4947.	4.1	31
25	Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1694-1704.	4.1	30
26	Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2228-2237.	4.1	28
27	ANG1005 for breast cancer brain metastases: correlation between 18F-FLTâ€“PET after first cycle and MRI in response assessment. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 51-59.	2.5	27
28	Pharmacogenomics and histone deacetylase inhibitors. <i>Pharmacogenomics</i> , 2016, 17, 1807-1815.	1.3	27
29	Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells. <i>Clinical Cancer Research</i> , 2016, 22, 1197-1210.	7.0	25
30	Opportunities for using in silicoâ€“based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1769-1777.	2.4	25
31	Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques. <i>Cytokine</i> , 2018, 108, 213-224.	3.2	23
32	Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. , 2021, 9, e003388.		23
33	A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 92, 63-68.	2.8	22
34	Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease. <i>PLoS ONE</i> , 2016, 11, e0152007.	2.5	22
35	A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. <i>Oncologist</i> , 2017, 22, 505-e49.	3.7	20
36	UGT1A1 genotypeâ€“dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 450-460.	2.0	19

#	ARTICLE	IF	CITATIONS
37	<p>Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro</p>. International Journal of Nanomedicine, 2020, Volume 15, 991-1003.	6.7	18
38	Development and validation of a simple, selective, and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1171, 122641.	2.3	16
39	A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. Blood, 2021, 137, 896-907.	1.4	15
40	Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. Clinical Cancer Research, 2021, 27, 3298-3306.	7.0	15
41	Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma. Molecular Cancer Therapeutics, 2020, 19, 2308-2318.	4.1	14
42	Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. Journal of Clinical Pharmacology, 2022, 62, 532-540.	2.0	14
43	A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 247-257.	2.8	13
44	Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. Journal of Neuro-Oncology, 2017, 132, 401-407.	2.9	12
45	PBPK modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug. Journal of Controlled Release, 2019, 308, 86-97.	9.9	12
46	Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2020, 181, 113073.	2.8	12
47	Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures. Molecular Cancer Research, 2020, 18, 1278-1289.	3.4	12
48	Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in <i>H/NRASQ61X</i> Mutant Rhabdomyosarcoma. Molecular Cancer Therapeutics, 2022, 21, 170-183.	4.1	12
49	Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. Clinical Genitourinary Cancer, 2020, 18, 258-267.e1.	1.9	11
50	Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain. Cancer Biology and Therapy, 2020, 21, 223-230.	3.4	10
51	Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma. Cancer Chemotherapy and Pharmacology, 2020, 85, 827-830.	2.3	10
52	Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2020, 86, 475-486.	2.3	10
53	A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models. Cancer Research, 2021, 81, 1076-1086.	0.9	10
54	Adenosine A2A Receptor Activation Enhances Blood–Tumor Barrier Permeability in a Rodent Glioma Model. Molecular Cancer Research, 2021, 19, 2081-2095.	3.4	10

#	ARTICLE	IF	CITATIONS
55	Efficacy and Safety of Baricitinib in Refractory Chronic Graft-Versus-Host Disease (cGVHD): Preliminary Analysis Results of a Phase 1/2 Study. <i>Blood</i> , 2020, 136, 1-1.	1.4	10
56	A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 927, 142-146.	2.3	9
57	Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 165-175.	2.3	9
58	Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 521-536.	1.8	9
59	A sensitive and rapid ultra high-performance liquid chromatography with tandem mass spectrometric assay for the simultaneous quantitation of cyclophosphamide and the 4-hydroxycyclophosphamide metabolite in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1086, 56-62.	2.3	9
60	Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 1003-1007.	2.3	9
61	Checkpoint inhibitor immunotherapy during pregnancy for relapsed refractory Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2022, 97, 833-838.	4.1	9
62	Quantification of Temozolomide in Nonhuman Primate Fluids by Isocratic Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry to Study Brain Tissue Penetration Following Intranasal or Intravenous Delivery. <i>Separations</i> , 2016, 3, 4.	2.4	8
63	Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. <i>Frontiers in Pharmacology</i> , 2016, 7, 260.	3.5	8
64	Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab. <i>BMC Pulmonary Medicine</i> , 2018, 18, 112.	2.0	8
65	Ibrutinib's off-target mechanism: cause for dose optimization. <i>Cancer Biology and Therapy</i> , 2021, 22, 529-531.	3.4	8
66	Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 970, 95-101.	2.3	7
67	A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 176-176.	1.6	7
68	A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 565-570.	2.3	6
69	Plasma and cerebrospinal fluid pharmacokinetics of the DNA methyltransferase inhibitor, 5-azacytidine, alone and with inulin, in nonhuman primate models. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa005.	0.7	6
70	A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2020, 149, 437-445.	2.9	5
71	A Quantitative Pharmacology Model of Exosome-Mediated Drug Efflux and Perturbation-Induced Synergy. <i>Pharmaceutics</i> , 2021, 13, 997.	4.5	5
72	Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects. <i>Cancer Biology and Therapy</i> , 2017, 18, 470-472.	3.4	4

#	ARTICLE	IF	CITATIONS
73	A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 759-770.	2.3	4
74	Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in <i>DPYD</i> . <i>Pharmacogenomics</i> , 2021, 22, 81-85.	1.3	4
75	Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclox-induced cytotoxicity in atypical teratoid/rhabdoid tumors. <i>Cell Death and Disease</i> , 2022, 13, 410.	6.3	4
76	Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy. <i>Cancer Biology and Therapy</i> , 2014, 15, 1117-1119.	3.4	3
77	Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 217-221.	2.3	3
78	Tissue preservation with mass spectroscopic analysis: Implications for cancer diagnostics. <i>Cancer Biology and Therapy</i> , 2018, 19, 953-955.	3.4	3
79	Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in persons with pancreaticobiliary cancer or other mesothelin expressing solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS452-TPS452.	1.6	3
80	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29282.	1.5	3
81	A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11552-11552.	1.6	3
82	Alemtuzumab clearance, lymphocyte count, and T-cell chimerism after hematopoietic stem cell transplant in sickle cell disease. <i>Pharmacotherapy</i> , 2022, 42, 14-22.	2.6	3
83	Flow Rate and Apparent Volume of Cerebrospinal Fluid in Rhesus Macaques (<i>Macaca mulatta</i>) Based on the Pharmacokinetics of Intrathecally Administered Inulin. <i>Comparative Medicine</i> , 2020, 70, 526-531.	1.0	3
84	Dose Optimization of Pembrolizumab: Less May Be More. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 993-993.	4.7	3
85	A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide. <i>Oncologist</i> , 2022, 27, 718-e694.	3.7	3
86	The androgen receptor transcriptional program in castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 16-18.	3.4	2
87	Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 215-218.	2.3	2
88	Local and Systemic Antitumor Effects of Photo-activatable Paclitaxel Prodrug on Rat Breast Tumor Models. <i>Photochemistry and Photobiology</i> , 2020, 96, 668-679.	2.5	2
89	Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single-Dose Administration Under Fasting Conditions in Prostate Cancer. <i>Oncologist</i> , 2021, 26, 729-e1493.	3.7	2
90	Phase I and pharmacokinetic study of sorafenib in Kaposi sarcoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10588-10588.	1.6	2

#	ARTICLE	IF	CITATIONS
91	Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment. Translational Oncology, 2022, 21, 101440.	3.7	2
92	A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 942-943, 107-112.	2.3	1
93	Jumping the Barrier: Modeling Drug Penetration across the Blood-Brain Barrier. Clinical Cancer Research, 2017, 23, 7437-7439.	7.0	1
94	Phase I trial of belinostat in combination with cisplatin (Cis) and etoposide (Etop).. Journal of Clinical Oncology, 2013, 31, 2527-2527.	1.6	1
95	Subcutaneous Atezolizumab: A Jab Without a Benefit. Clinical Pharmacology in Drug Development, 2022, 11, 134-135.	1.6	1
96	A simple and rapid UHPLC-MS/MS method for the quantitation of the dual aurora kinase A/B inhibitor SCH-1473759 in murine plasma. Journal of Pharmaceutical and Biomedical Analysis, 2017, 132, 223-226.	2.8	0
97	Effects of Alvelestat, an Oral Neutrophil Elastase Inhibitor, on Elevated Elastase and Collagen Turnover Biomarkers in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Blood, 2021, 138, 1815-1815.	1.4	0
98	Phase 1 Study of Alvelestat, an Oral Neutrophil Elastase Inhibitor, in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Blood, 2020, 136, 18-19.	1.4	0
99	Quantitation of the next-generation imipridone ONC206 in human plasma by a simple and sensitive UPLC-MS/MS assay for clinical pharmacokinetic application. Journal of Pharmaceutical and Biomedical Analysis, 2022, 213, 114685.	2.8	0
100	DDEL-04. Pharmacokinetic/Pharmacodynamic analysis of the DNA methyltransferase inhibitor 5-azacytidine shows adequate brain tissue penetration with intravenous administration in a DIPG mouse patient-derived xenograft model.. Neuro-Oncology, 2022, 24, i34-i34.	1.2	0